Fexuprazan

Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD).^[1] It is a potassium-competitive acid blocker,^[2] which is a class of drugs suppressing gastric acids.^[3][4]

Fexuprazan

Clinical data
Trade names	Fexuclue
Other names	Abeprazan; DWP14012; DWP-14012
ATC code	A02BC10 (WHO)
Legal status
Legal status	Rx in South Korea, Mexico
Identifiers
IUPAC name 1-[5-(2,4-Difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine
CAS Number	1902954-60-2
PubChem CID	122662112
DrugBank	DB16078
ChemSpider	68006985
UNII	BE52S2C1QT
KEGG	D13012
ChEMBL	ChEMBL4594445
Chemical and physical data
Formula	C19H17F3N2O3S
Molar mass	410.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F
InChI InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3 Key:OUNXGNDVWVPCOL-UHFFFAOYSA-N

Fexuprazan is approved for clinical use in South Korea,^[4][5] Mexico,^[6] Philippines,^[7] Chile,^[8] and Ecuador.^[9]